The vitreous is a complex structure whose composition and appearance change with age. Anomalous adhesions between the posterior vitreous face and the retinal surface are the cause of numerous vitreoretinal complications, while the presence of an intact posterior hyaloid provides a scaffold for vascular growth and anteroposterior traction. This review summarizes what is known about the biochemistry of the vitreous, the process of posterior vitreous detachment (PVD) development, and the available clinical approaches to examining the vitreous and its interface. A pooled analysis of studies looking at the presence of a complete, partial or absent PVD in a number of macular and retinal diseases allows us to establish odds ratios for these various states. From this emerge both protective and disease-associated states in conditions such as proliferative diabetic retinopathy, macular edema, and age-related macular degeneration. With the emergence of pharmacological means to separate the posterior hyaloid, a better understanding of the possible role of the vitreous in tractional syndromes is required.

Within the eye, no other component occupies as much space as the vitreous; eye movements induce incessant stress forces, and with age, its composition and structure change. Its role in the physiology and pathobiology of the eye is being increasingly appreciated, but its study is complicated due to its invisible nature. Vitreous liquefaction and posterior vitreous separation have particularly important consequences for ocular health and disease. Modifying the intraocular structure by ever evolving therapeutic modalities has reduced the incidence of blindness. While in the future, the vitreous will be modified by pharmacological means, their success will depend on an adequate understanding of its physiological and pathological role in vitreoretinal disorders.

Vitreous Composition

The vitreous is the largest structure within the eye occupying about 80% of the ocular volume [1]. It is a highly hydrated transparent extracellular matrix containing 98-99% water [2]. Its gel structure is maintained by a 3-dimensional network of randomly spaced, nonbranching collagen fibrils, held apart by hyaluronan (HA) and other macromolecules. The collagen concentration is low, approximately 300 µg/ml [3], with type II collagen being the main component [4,5]. The distribution within the eye is not uniform, the highest concentration being present at the vitreous base followed by the posterior vitreous cortex, and the vitreous core [3]. This network of collagen fibers provides the vitreous with mechanical strength, allowing it to sustain impacts, and transmit tractional forces to the retinal surface [2].

HA is the major glycosaminoglycan present in the mammalian vitreous [6]. It serves to inflate and stabilize the collagen network [7,8]. The adult human vitreous has a HA concentration ranging between 65 and 400 µg/ml with the highest concentration present in the posterior cortical vitreous [7]. HA-collagen interactions insure proper hydration and spacing, thus decreasing light scattering and enhancing transparency. It also provides the vitreous with its viscoelastic properties [6,8,9]. Other molecules such as opticin are also present in the human vitreous and help to further stabilize its structure [7,9].

The vitreous is acellular except for a sparse population of hyalocytes, oval to spindle-shaped mononuclear cells measuring 10-15 µm in diameter. These phagocytic cells are mostly concentrated in the vitreous base and adjacent to the posterior pole [6,7,10,11]. They are involved in the synthesis of vitreous components such as collagen fibrils, HA and other macromolecules, and have been implicated in a number of pathological eye conditions [12].

Vitreoretinal Interface

The vitreous is surrounded by the lens, ciliary body anteriorly and by the retina. The interface between the vitreous and its surroundings is composed of vitreous cortical fibrils and the basal laminae of the adjacent tissues [13]. The internal limiting lamina (ILL) of the retina formed mainly by the basal lamina of Müller cells [14] is composed of collagen types I and IV, proteoglycans, fibronectin, and laminin [15,16,17,18]. These and other components of the extracellular matrix are the targets of pharmacological posterior vitreous detachment (PVD) with agents such as plasmin, microplasmin, and dispase. They may eventually replace the conventional surgical induction of PVD [19,20,21,22,23,24,25]. The ILL varies in thickness and composition. At the vitreous base, it measures about 50 nm and progressively thickens as one follows it posteriorly, measuring 300 nm at the equator, 1,890 nm at the posterior pole. It thins again over the fovea to about 10-20 nm [13,23,26]. Over the optic nerve, the inner limiting membrane is 50 nm thick and is formed by the basal lamina of the astroglia present on the surface of the nerve (ILL of Elschnig). At the most central part of the optic nerve, the membrane thins to 20 nm and follows the irregularities of the underlying cells. This structure is known as the central meniscus of Kuhnt and is composed of only glycosaminoglycans [13,27].

Firm vitreoretinal attachments are observed in areas with thin ILL as occurs at the vitreous base, optic disk, fovea, and over the major retinal blood vessels [28]. At the vitreous base, collagen fibrils are coarse, numerous, and run perpendicularly to the ILL; in the equatorial and posterior regions, the fibrils are finer and almost parallel to the retinal surface [29]. Attachment plaques between Müller cells and the ILL are present everywhere except in the macula [13,28,30].

Aging Vitreous and Its Consequences

The aging vitreous both liquefies and aggregates. Synchysis, the process of vitreous gel liquefaction, first appears at around 4 years of age. The process begins in midlife and in most cases progresses slowly into late age [31,32]. Aggregation (syneresis) is a consequence of changes in the chemical or conformational state of HA and its interaction with collagen. These alterations lead to increased fibril concentration in the residual gel, associated with a decreased concentration and ultimate absence of fibrils in adjacent areas resulting in liquefaction [33,34]. As liquefaction appears in the central vitreous and overlying the macula, incident light weakens collagen through the production of free radicals [35,36,37,38], and modifies the concentrations in glycosaminoglycans and chondroitin sulfate [39]. Artificially inducing such changes leads to vitreous liquefaction and separation of the posterior hyaloid [22,40,41].

PVD refers to the separation of the posterior vitreous cortex from the ILL of the retina. Two clinical entities may be confused with, but should be distinguished from, a true PVD [42]. First, vitreoschisis consists in a split of the posterior vitreous cortex into two independent layers - an anterior layer moving forward with the bulk of the vitreous gel, and a posterior layer remaining attached to the ILL. It is often observed in high myopia and connective tissue disorders or in other situations where the vitreous is rapidly or extensively liquefied (proliferative diabetic retinopathy, vitreous hemorrhage) where it may contribute to the disease process [43,44,45,46,47,48]. The second entity occurs when the vitreous separates together with the ILL from the retinal surface. This most commonly occurs in younger individuals in whom significant tractional forces were exerted at the retinal surface as in trauma due to blunt ocular injuries or in the setting of inner retinal ischemia. Under these extreme circumstances, Müller cells have weakened inner segments, which can separate from the retinal surface if sufficient shearing forces are applied [49].

Most PVDs evolve from an interplay between vitreous synchysis and weakening of the adhesions between the posterior vitreous cortex and the ILL. Once liquefied, premacular vitreous can find its way to the retrohyaloid space through either the central meniscus of Kuhnt, or through a break in the thinned posterior vitreous cortex overlying the macula. With successive ocular saccades, further fluid shifts dissect a plane through the preretinal space leading eventually to a complete PVD (CPVD) [50,51,52]. As a consequence of these fluid movements, the remaining gel undergoes collapse and moves forward [35,53]. In a study on 61 postmortem human eyes, Larsson and Österlin [53] found that the degree of vitreous liquefaction increased with the degree of PVD: no PVD (NPVD), partial PVD (PPVD), and complete PVD (CPVD) corresponded to 10, 23 and 42% of gel liquefaction.

Floaters and photopsias are the most common symptoms reported with the abrupt onset of a PVD [54]. Floaters are caused by aggregations of collagen fibrils, epiretinal glial tissue adherent to the posterior vitreous cortex and small dome-shaped posterior hyaloid elevations which scatter light before it reaches the retina (fig. 1). Murakami et al. [55] found a PVD in 83% of eyes following a sudden onset of floaters. The incidence is higher in patients above 50 years of age (95%). Most floaters originate from condensed vitreous material located a short distance from the retinal surface (fig. 1b) [56]. Under these conditions, incident light causes a conal shadow to form behind the floater, which is visible on the retinal surface (fig. 2). With increasing separation between the floater and the retinal surface, this shadow vanishes rendering the floater invisible. Surrounding the shadow, the penumbra, which usually blends into an uneven background, may become visible on a uniform white background. Smaller pupil sizes, as occurs with intense light will cast a conal shadow over a longer distance, allowing floaters to reappear.

Fig. 1

Depending on their position and size, floaters are capable of casting a shadow on the retinal surface and be perceived by the OCT. a On the scanning laser ophthalmoscopy image, a floater is visible inferotemporal to the macula and is visible to the left of the macula on the corresponding image but is not visible within the vitreous. b In asteroid hyalosis only large condensation causes a shadow on the retinal surface (arrows). c Shallow elevations of the posterior hyaloid also cause patients to complain of shadows that are fixed in position when the eye moves.

Fig. 1

Depending on their position and size, floaters are capable of casting a shadow on the retinal surface and be perceived by the OCT. a On the scanning laser ophthalmoscopy image, a floater is visible inferotemporal to the macula and is visible to the left of the macula on the corresponding image but is not visible within the vitreous. b In asteroid hyalosis only large condensation causes a shadow on the retinal surface (arrows). c Shallow elevations of the posterior hyaloid also cause patients to complain of shadows that are fixed in position when the eye moves.

Close modal
Fig. 2

Schematic diagram showing the effect of the pupil size on the conal shadow cast behind a floater onto the retinal plane. The small circles next to the retinal plane indicate the size of the shadow in relationship to the size of the floater if the retina was present in this particular plane. In the upper panel, the pupil is drawn 1.5 times larger than in the lower panel, all other scales are kept intact. The conal shadow is narrower and longer in the lower panel which allows floaters to be more visible and appear larger. It also allows floaters further distant from the retinal surface to be visualized in strong light causing a smaller pupillary opening. Adapted from Serpetopoulos [160].

Fig. 2

Schematic diagram showing the effect of the pupil size on the conal shadow cast behind a floater onto the retinal plane. The small circles next to the retinal plane indicate the size of the shadow in relationship to the size of the floater if the retina was present in this particular plane. In the upper panel, the pupil is drawn 1.5 times larger than in the lower panel, all other scales are kept intact. The conal shadow is narrower and longer in the lower panel which allows floaters to be more visible and appear larger. It also allows floaters further distant from the retinal surface to be visualized in strong light causing a smaller pupillary opening. Adapted from Serpetopoulos [160].

Close modal

Photopsias caused by vitreoretinal traction are an ominous sign of a retinal tear, particularly when associated with the appearance of multiple floaters [57,58,59]. Photopsias in this context are often reported as lightning streaks, vertical or oblique. In the first 24 h, astute observers have described them as ‘dark light flashes' [56,60]. As opposed to flashes from other causes, they are often better perceived in the dark, fleeting in nature, and colored [61].

Stages of PVD

Early Stages of PVD

Age-related PVD usually starts as a shallow perifoveal separation. Early on, the posterior vitreous face separates from the perifoveal area but maintains residual attachments to the fovea and the optic disk (fig. 3, panel A) [38,62,63]. If persistent, these perifoveal attachments pull on the fovea through dynamic tractional forces exerted during ocular saccades. Progression to a CPVD is a slow process, leaving plenty of time for such tractional forces to cause damage such as macular holes or edema. Of 31 eyes with perifoveal vitreous detachment followed prospectively, only 3 evolved to a CPVD over a 30-month period [64].

Fig. 3

Schematic diagrams illustrating different stages of PVD. A Macular PVD. a PVD at the level of the macula begins in a perifoveal location. b The PVD extends itself to the optic nerve. c Further extension occurs temporally. d Even after the fovea has become detached, attachments around the nerve may persist for a prolonged period of time before there is complete detachment from the optic nerve. B PVD extension beyond the macular area. a PVD starts in the foveal and parafoveal area. At this stage, an attachment to the fovea is often present. b The detachment most often extends first in a superior direction. At this stage, the fovea may still be attached to the posterior hyaloid. c The PVD extends further in a superotemporal and nasal direction. The foveal attachments are often gone by this stage. d Extension continues in an inferotemporal direction before extending further nasally (not shown). C CPVD. It may take on a number of different appearances depending on the etiology underlying its formation. a Complete vitreous detachment with collapse characterized by a sigmoidal shape posterior hyaloid. b CPVD without collapse which is shallowly detached and poorly motile. c PPVD with a taut posterior vitreous cortex. d PPVD with attachment at the macula. Adapted from Kakehashi et al. [67], Johnson [32] and Ito et al. [65].

Fig. 3

Schematic diagrams illustrating different stages of PVD. A Macular PVD. a PVD at the level of the macula begins in a perifoveal location. b The PVD extends itself to the optic nerve. c Further extension occurs temporally. d Even after the fovea has become detached, attachments around the nerve may persist for a prolonged period of time before there is complete detachment from the optic nerve. B PVD extension beyond the macular area. a PVD starts in the foveal and parafoveal area. At this stage, an attachment to the fovea is often present. b The detachment most often extends first in a superior direction. At this stage, the fovea may still be attached to the posterior hyaloid. c The PVD extends further in a superotemporal and nasal direction. The foveal attachments are often gone by this stage. d Extension continues in an inferotemporal direction before extending further nasally (not shown). C CPVD. It may take on a number of different appearances depending on the etiology underlying its formation. a Complete vitreous detachment with collapse characterized by a sigmoidal shape posterior hyaloid. b CPVD without collapse which is shallowly detached and poorly motile. c PPVD with a taut posterior vitreous cortex. d PPVD with attachment at the macula. Adapted from Kakehashi et al. [67], Johnson [32] and Ito et al. [65].

Close modal

Late Stages of PVD

The extension from the macula to the periphery generally follows a specific pattern. Extension first occurs to the arcades, where attachments between the posterior hyaloid and the adventitia of vessels may retain the hyaloid for a while. From there, extension progresses first upwards towards 12 h before moving temporally. Nasal and inferior quadrants are the last to witness vitreous separation [65] (fig. 3, panel B). This pattern of detachment helps explain why iatrogenic tears in macular hole surgery tend to be located inferiorly rather than in superior quadrants [66]. In these patients, PVD is often incomplete particularly with smaller holes. During surgery, a PVD is often deliberately and energetically induced leading to the formation of tears, as the vitreous retains firm adhesions to the inferior peripheral retina.

Optical Coherence Tomography and Biomicroscopic Classification of PVD

Biomicroscopically, PVD is often classified into 1 of 4 patterns based on findings in the vitreous proper and at the posterior hyaloid (fig. 3, panel C) [67]. With optical coherence tomography (OCT), a similar classification has been proposed but depends on the ability to visualize the interface. PPVDs are clearly visible, but absent PVDs or CPVDs with vitreous collapse beyond the limits of the scanning area imposed by the machine would appear the same. It is important to obtain multiple scans, preferably a stack allowing transverse imaging as this may provide additional information (see the section on clinical assessment by OCT below) [68,69,70]. Scanning over the optic nerve looking for residual attachments at this level is also important.

(1) A CPVD with vitreous collapse is characterized by vitreous lakes, the presence of a Weiss ring, and a large retrohyaloid space. The posterior hyaloid often has a sigmoidal shape and is highly motile. This type is commonly seen in elderly people and in high myopia.

(2) CPVD without vitreous collapse is characterized by minimal vitreous liquefaction, a clearly defined retrohyaloid space, and the presence of a Weiss ring. The posterior hyaloid is located a short distance from the retinal surface and lacks much motility. This type is characteristic of patients with uveitis or retinal vein occlusions where the increased blood components or inflammatory cells cause a separation of the posterior hyaloid without significant vitreous liquefaction.

(3) PPVD with a taut posterior hyaloid has anchoring points present to the optic disk, the vascular arcades, and/or neovascular complexes. It is typically seen in patients with proliferative diabetic retinopathy.

(4) PPVD without a taut hyaloid shows vitreomacular attachments still present through the premacular hole to the fovea, and elsewhere, particularly at the optic nerve [68,70,71,72].

Epidemiology

Classical studies suggested an incidence of about 50% at the age of 50, and 65% beyond 65 years [73]. Use of OCT has shown that PVD is a much slower process requiring several decades for completion in most individuals [31,72,74]. In pathological states, the process will initiate itself earlier, as in myopia, where the age of onset depends on the degree of myopia [54,75,76]. On average emmetropes initiate their PVD around 61 years of age, while for a -5-dpt myope, it starts at 56 years, for -10 dpt at 52 years, for -20 dpt at 43 years, and for -30 dpt at 34 years [77]. A higher incidence of PVD has been observed in women, occurring also at a lower age than men, a finding that may be related to hormonally controlled changes in HA concentrations occurring around the menopause [77,78,79,80]. PVD is 7-10 times more frequent in aphakic as compared to phakic eyes [38], likely as a result of changes in the composition of the vitreous following cataract extraction. In pseudophakics, a very fluid vitreous and a PVD develop within about 18-24 months after surgery. The exact rate of change is influenced by the type of extraction, the state of the posterior capsule, and the degree of myopia [81,82,83,84].

Aberrant PVD and Its Consequences

Widespread synchysis can lead to a separation of the vitreous gel from the retinal surface without release of the vitreoretinal interface - an anomalous PVD [85]. In such cases (table 1), traction is exerted at the interface between the zone of vitreous liquefaction and vitreoretinal adherence, a phenomenon known as vitreomacular traction. If the forces exerted are sufficiently strong, they lead to the development of tears, retinal hemorrhages, retinal neovascularization, macular or lamellar holes, edema, or other deleterious effects depending on the traction's location [48,85,86,87]. In addition, an anomalous PVD leaves the outer layer of the posterior vitreous cortex attached to the retina (vitreoschisis) [88]. Contraction of this layer onto the retinal surface, or its use as a scaffold, can lead to the formation of an epiretinal membrane or tangential tractional complexes as seen in high myopia (fig. 4). Excessive gel liquefaction is observed in a number of circumstances such as with inborn errors in collagen metabolism (Stickler's, Marfan's, and Ehlers-Danlos syndromes) [89,90], intraocular inflammation [91,92], diabetes [93], ocular trauma [94], and in high myopia [75].

Table 1

Vitreoretinal consequences of anomalous PVD

Vitreoretinal consequences of anomalous PVD
Vitreoretinal consequences of anomalous PVD
Fig. 4

Vitreous liquefaction often occurs earlier than posterior vitreous separation in high myopes leading to the formation of thick posterior hyaloidal membranes which have a very elastic nature when removed surgically.

Fig. 4

Vitreous liquefaction often occurs earlier than posterior vitreous separation in high myopes leading to the formation of thick posterior hyaloidal membranes which have a very elastic nature when removed surgically.

Close modal

Slitlamp Biomicroscopy

Several lenses have been developed to enhance the ability to see the central and posterior vitreous (table 2). Depending on the lens configuration, an erect or inverted, real or virtual image is produced. Most of these have fallen into disfavor given the availability of OCT, but they are useful to rapidly gain an understanding of the vitreous proper in 3 dimensions, particularly beyond the region visible with current imaging systems.

Table 2

Characteristics of various lens types used to examine the vitreous and the vitreoretinal interface

Characteristics of various lens types used to examine the vitreous and the vitreoretinal interface
Characteristics of various lens types used to examine the vitreous and the vitreoretinal interface

To optimally examine the vitreous, it is best to use a systematic approach. First, the central region is examined, identifying the presence or absence of vacuolation (synchysis), and/or a PVD. If the latter is present, the extent of detachment can be determined by following the posterior vitreous cortex peripherally. Rocking the lens, and using a large slit beam can enhance visualization of the posterior cortex. Visualization of the premacular cortex can best be done by retroillumination using reflected light from the retinal surface on an appropriately magnified image. Visualization of the peripheral vitreous is accomplished by using wide-field lenses, but this is more difficult to detect and will only be clearly seen in cases where the central PVD was visible at the level of the posterior vitreous cortex.

Optical Coherence Tomography

Clinically relevant vitreomacular adhesions, macular holes, and pseudoholes have been documented by conventional time domain OCT [70,95,96,97,98]. A posterior hyaloid membrane is seen in 57% of patients with idiopathic macular holes on OCT but is detected biomicroscopically in less than half of these patients [99,100,101]. Although time domain OCT can visualize the vitreomacular interface including the posterior hyaloid, information is limited by the relatively slow scan speed and poor image registration. Alternate scanning strategies combined registration with a scanning laser ophthalmoscope, the use of multidepth scanning with spectral domain OCT, or the use of broad-band light sources provide a more detailed view of the retinal surface [102,103,104,105].

Media opacities have an influence on image quality irrespective of the scanning technique. Corneal opacities or drying has substantially more effect than cataracts [106]. Vitreous opacities unless they are dense in nature, and in close proximity to the retina, have limited effect on the quality of the signal generated (fig. 1).

The OCT characteristics of vitreomacular traction are shown in figure 5. At the retinal surface, the vitreoretinal interface shows as a discrete reflective line above the nerve fiber layer with which it has either a number of discrete attachments points, or forms a broad firm attachment [103,107,108]. A broad insertion is more likely to be associated with macular edema or to lead to macular hole formation. Using 3-dimensional surface rendering, the number of attachment points between the posterior hyalooid and the retinal surface can be determined. These attachments are also relevant in macular pucker where more points of attachment are associated with a worse visual prognosis [102].

Fig. 5

Two- and 3-dimensional spectral OCT images of macular traction. In all images the posterior hyaloid is visible. a The vitreous passes through a narrow opening in the posterior hyaloid and causes persistent traction on the fovea. b The area of posterior hyaloid attachment is broader. Coarse retinal ridges represent attachments of the vitreous to the retina. Finer attachments between the retina and posterior hyaloid. Fine ridges on the retinal surface in both panels are due to an epiretinal membrane.

Fig. 5

Two- and 3-dimensional spectral OCT images of macular traction. In all images the posterior hyaloid is visible. a The vitreous passes through a narrow opening in the posterior hyaloid and causes persistent traction on the fovea. b The area of posterior hyaloid attachment is broader. Coarse retinal ridges represent attachments of the vitreous to the retina. Finer attachments between the retina and posterior hyaloid. Fine ridges on the retinal surface in both panels are due to an epiretinal membrane.

Close modal

Ultrasound

Ultrasound has traditionally been used to determine the state of the vitreous, and to identify the presence and extent of a PVD. Strong echoes are produced by ‘acoustic' interfaces found at the junctions of media with different densities and sound velocities. The greater the difference in density between two media, the more prominent the echo [109]. Contact B scan is superior to biomicroscopy and OCT even in the absence of media opacity [110]. It is the technique of choice in cases with vitreous hemorrhage [111]. The signal can be enhanced following the injection of triamcinolone into the vitreous cavity, and might be an interesting adjunctive diagnostic technique in patients requiring surgery [112]. In a study of 94 patients to evaluate the relationship between the posterior hyaloid membrane and the retina in patients with idiopathic macular hole, a persistent attachment to the foveola with perifoveolar PVD was evident by ultrasound in 83 and 67% of patients with stage 1 and 2 holes, respectively [113]. Additionally, axial views identified a separation of the posterior hyaloid membrane from the perifoveal retina in 13 out of 13 (100%) patients with stage 1 and 2 holes, separation of the posterior hyaloid membrane from the fovea and perifoveal retina with peripapillary attachment was evident by ultrasound in 65 out of 65 (100%) patients with stage 3 hole. The advent of high-resolution OCT scans over a larger area particularly when it includes the optic nerve may well supplant the use of the ultrasound in most cases [70,72,114,115.]

The posterior hyaloid has been implicated in a number of macular diseases. Its role is mentioned in scattered case reports, small case series, and a few prospective studies. It is difficult to assess in a reliable way the risk and benefits associated with PPVD or CPVD from such varied sources.

In order to quantify the benefits of PVD, and establish odds ratios (ORs) associated with PPVD or CPVD, a systematic review of the literature was undertaken using the following methodology. A broad systematic review method was used to cover the literature between 1980 and October 2012 in Embase, Medline and Web of Science. Studies were identified in these databases using cross-references from original articles and reviews. We identified 609 articles of which 130 were reviewed in detail, allowing us to retain 56 for further analysis. Only 39 were used to produce the statistical analysis reported below.

The search strategy to identify articles used the following terms:

• Spontaneous posterior vitreous detachment

• Vitreous body detachment

• Posterior vitreous face detachment

• Posterior hyaloid face detachment

• Corpus vitreum detachment

In the current analysis, we used prospective studies, retrospective analyses of data from randomized controlled trials, observational studies, and case report studies evaluating the association between spontaneous PVD and disease course. Only English language articles were used, except for age-related macular degeneration (AMD) where due to the limited number of articles available on the subject, a German language article was also included. After excluding editorials, conference proceedings, letters, news articles, government reports, and practice guidelines, two investigators (M.dS. and A.G.) independently screened titles and abstracts to identify potentially relevant citations. Data of eligible articles was formatted in terms of absence (NPVD), the presence of a PPVD or CPVD and its effect on prevalence, incidence or outcomes in specific ocular conditions determined based on the availability of sufficient data. CPVD was defined as a complete separation of the posterior vitreous cortex from the ILL of the retina in the posterior pole. PPVD referred to cases that were described in sufficient details by the authors as having an incomplete separation of the posterior hyaloid from the retinal surface. In each disease, we calculated the weighted OR over the available studies using the fixed-effects model, and tested the assumed homogeneity between studies with a Q test. The results of these analyses are given in table 3.

Table 3

State of vitreoretinal traction and the relative risk of retinal pathologies (expressed in ORs)

State of vitreoretinal traction and the relative risk of retinal pathologies (expressed in ORs)
State of vitreoretinal traction and the relative risk of retinal pathologies (expressed in ORs)

Influence of PVD on Retinal Neovascularization

Neovascularization on the retinal surface cannot occur without an appropriate scaffold of collagenous material. Hence, the presence of a PVD should provide relative protection in susceptible individuals, particularly if associated traction is removed. In proliferative diabetic retinopathy, 5 studies were identified for a total of 2,188 eyes, in which the state of the posterior hyaloid (CPVD, PPVD, or NPVD) was studied in terms of its association with concomitant proliferative or nonproliferative diabetic retinopathy (table 3) [116,117,118,119]. Pooled analysis of these 5 studies found that diabetic patients having CPVD indeed had a statistically significant lower prevalence of proliferative disease compared to NPVD (OR 0.1, 95% confidence interval, CI, 0.05-0.18). By opposition, patients with PPVD had a 24 time greater prevalence of proliferative disease than those with NPVD. The difference with patients who had CPVD was considerably higher at 186. The effect of PVD on progression of proliferative disease was examined in 2 studies with a minimum of 6 months of follow-up [116,120]. Only patients with active proliferative diabetic retinopathy were included in these studies. Pooling allowed calculation of an OR for 312 eyes. Progression of proliferative diabetic retinopathy was significantly associated with NPVD or PPVD (OR 0.3, 95% CI 0.09-0. 91). PPVD had a 6 times higher rate of progression than NPVD, but a 15 times higher rate than CPVD.

Five studies were identified that looked at the association of PVD with neovascularization in vein occlusions [121,122,123,124,125]. Patients included in these studies had ischemic retinal vein occlusions, were followed up for a minimum of 6 months (range 6-97), and were classified based on the presence or absence of a PVD without reference to the extent of PVD. In total 209 eyes were reported. The presence of a PVD at the onset of the follow-up period significantly reduced the risk of developing neovascularization (OR 0.06, 95% CI 0.02-0.15). Of interest, Kado et al. [126] studied the effect of retinal vein occlusion on the posterior vitreous status in 26 patients and compared it with 18 normal individuals with NPVD at the initial examination (no retinal vein occlusion) over a 1-year period. They found that 58.5% of patients with a vein occlusion developed CPVD by 6 months, with 69.6% having a PVD by 12 months as compared to 25% in the control group at both 6 and 12 months of follow-up. Records of patients undergoing an optic neurotomy or arteriovenous sheath separation indicated that the vast majority of patients had an intact posterior vitreous face prior to surgery (central retinal vein occlusion 56/61 patients; branch retinal vein occlusion 35/38) [127], an incidence which according to the authors is much higher than expected from historical controls obtained by ultrasonography. Imaging using spectral-domain OCT revealed a high frequency of perifoveal traction but was less frequently identified than with surgery [128]. Clearly, observations made at the time of surgery are superior to imaging techniques when it comes to the assessment of the posterior hyaloid. It may serve as a reference to assess the positive and negative predictive values of novel imaging techniques with regard to PVD.

Influence of PVD on Macular Edema

The spontaneous release of vitreomacular traction in the presence of cystoid edema often leads to an improvement in vision [129,130,131,132,133,134]. Six studies were identified which looked at the prevalence of PVD in patients with macular edema caused by diabetic retinopathy or retinal vein occlusion [63,135,136,137,138,139]. In total 615 eyes were identified. The risk of macular edema was reduced in patients with a PVD. Here, in contrast to proliferative disease, there was no significant difference between the presence of a PPVD or CPVD in terms of the associated OR (table 3).

The effect of a spontaneous PVD on the persistence of macular edema in a number of ocular pathologies (diabetic retinopathy, retinal vein occlusion, vitreomacular traction, and peripheral uveitis) was sufficiently well reported to allow analysis of 12 papers [123,125,126,129,130,133,140,141,142,143,144]. A total of 341 eyes with NPVD at the initial examination were reported with a follow-up extending for 1-110 months. Pooled analysis from these 12 studies indicates that macular edema is associated with a PPVD or absent PVD (OR 0.30, 95% CI 0.16-0.57).

PVD and Macular Holes

In stages 1 and 2 macular holes, 96% or more of eyes have only a perifoveal PVD, as shown by high-resolution OCT imaging [145]. Progression to a CPVD is a slow process potentially leading to the development of a full-thickness hole. In 31 eyes with perifoveal vitreous detachment followed prospectively, only 3 showed progression to CPVD over an average of 30 months [64]. Studies based on clinical observation alone already showed that small holes were associated with an attached posterior hyaloid. Two studies [146,147] with a combined total of 502 eyes, compared the state of the posterior vitreous cortex (complete, partial, or absence of detachment) between patients with idiopathic macular holes and normal control subjects. A pooled analysis of these 2 studies using the fixed effects model found that patients with idiopathic macular hole were twice as likely to have an intact or partially detached posterior hyaloid (OR 0.455, 95% CI 0.314-0.660).

Three studies [65,148,149], on 469 eyes, looked at the state of the posterior vitreous cortex (complete detachment vs. partial or absent) in relation to the stage of idiopathic macular hole. Pooled analysis from these 3 studies found that patients with stage 1 and 2 macular holes had a significantly higher incidence of NPVD (OR 0.034, 95% CI 0.009-0.12) than stage 3 and 4 macular holes.

Four studies [140,150,151,152], on 178 eyes, considered the state of the posterior vitreous cortex (PVD or NPVD) in early stages of macular hole formation (I and II) and the incidence of progression or resolution over a 3- to 240-month follow-up. Patients having a PVD or vitreofoveal separation at the initial examination or who developed a PVD during the follow-up period were less likely to progress. Absence of a PVD was associated with an OR of 0.08 and a 95% CI of 0.037-0.17. Closure of the macular hole was significantly associated with CPVD. High-resolution OCT suggests that despite a perifoveal detachment, a persistent attachment of the posterior hyaloid may remain at the edge of the hole and contribute to its progression towards stage IV. This is more frequent when an attachment persists at the edge of the optic nerve [46,145]. Such findings are absent in macular pucker, where a CPVD is seen in a majority of patients [153].

PVD and AMD

The association between an incomplete PVD and exudative AMD was first recognized in 1996. The clinical picture was ascertained with contact lens biomicroscopy, and the state of the vitreous using a 10-MHz dynamic B scan ultrasonogram [154]. A significantly higher incidence of incomplete PVD was found in patients with macular degeneration (p = 0.006). We identified 4 studies that looked at the state of the posterior hyaloid in patients with macular degeneration [154,155,156,157]. Three of the 4 studies used the ultrasound to assess the posterior vitreous, while 1 study used exclusively the OCT [155]. In total 332 eyes with AMD were studied and compared to age-matched controls. The OR was 0.46 in favor of a CPVD, a similar figure to that observed with macular hole formation in affected patients versus a control population. Two studies compared exudative versus nonexudative AMD. A pooled analysis of these 200 patients gives an OR of 0.5 in favor of a PVD [157,158]. One of these studies looked at the state of the macular area with the OCT, allowing for a more detailed analysis of anomalous vitreous insertion [157]. Partial or persistent adhesion in the foveal area was up to 10 times more likely in the exudative form of AMD. While the posterior hyaloid may play a role in wet AMD, it does not seem to have an influence on polypoidal choroidal vasculopathy, where the incidence of vitreomacular adhesion is the same between affected eyes and controls [159].

The vitreous and the posterior hyaloid are intimately linked to a number of ocular processes. As the largest structure within the eye, it is subjected to constant physical strain and undergoes significant changes with age. Physiological changes start early in life, and can have profound consequences on ocular homeostasis. A PVD may be of benefit in AMD, its absence is clearly associated with an increased risk of proliferative disease in diabetes and retinal vein occlusion. For proliferative diabetic retinopathy, a PPVD is associated with a significantly higher risk of proliferation than in its absence. Medical interventions, particularly surgical ones, have already improved the prognosis in a number of these conditions. Ideally, prevention by timely induction of a PVD, prior to the onset of these ocular diseases, might significantly reduce morbidity without the need of surgery. This is what pharmacological vitreolysis may provide. Armed with the knowledge on the role of both the vitreous and the posterior hyaloid on the natural history of ocular diseases, it will be possible to assess adequately new therapeutic modalities as they become available.

1.
Sebag J: Macromolecular structure of vitreous. Prog Polym Sci 1998;23:415-446.
2.
Bishop PN: The biochemical structure of the mammalian vitreous. Eye 1996;10:664-670.
3.
Hikichi T, Akiba J, Ueno N, Yoshida A, Chakrabarti B: Cross-linking of vitreous collagen and degradation of hyaluronic acid induced by bilirubin-sensitized photochemical reaction. Jpn J Ophthalmol 1997;41:154-159.
4.
Balasz E: Importance of the Vitreous Body in Retinal Surgery with Special Emphasis on Re-Operations. St Louis, Mosby, 1960.
5.
Bishop PN, Crossman MV, McLeod D, Ayad S: Extraction and characterization of the tissue forms of collagen types II and IX from bovine vitreous. Biochem J 1994;299:497-505.
6.
Bishop PN, Holmes DF, Kadler KE, McLeod D, Bos JK: Age-related changes on the surface of vitreous collagen fibrils. Invest Ophthalmol Vis Sci 2004;45:1041-1046.
7.
Sebag J: The Vitreous - Structure, Function and Pathobiology. New York, Springer, 1989.
8.
Bishop PN: Structural macromolecules and supramolecular organisation of the vitreous gel. Prog Ret Eye Res 2000;19:323-344.
9.
Comper WD, Laurent TC: Physiological function of connective tissue polysaccharides. Physiol Rev 1978;58:255-315.
10.
Theopold H, Faulborn J: Scanning electron microscopic aspects of the vitreous body: technique of preparation. Von Graefes Arch Klin Exp Ophthalmol 1980;214:33-38.
11.
Balazs EA, Toth LZ, Eckl EA, Mitchell AP: Studies on the structure of the vitreous body. XII. Cytological and histochemical studies on the cortical tissue layer. Exp Eye Res 1964;3:57-71.
12.
Kita T, Hata Y, Miura M, Kawahara S, Nakao S, Ishibashi T: Functional characteristics of connective tissue growth factor on vitreoretinal cells. Diabetes 2007;56:1421-1428.
13.
Grabner G, Boltz G, Förster O: Macrophage-like properties of human hyalocytes. Invest Ophthalmol Vis Sci 1980;19:333-340.
14.
Sebag J: Anatomy and pathology of the vitreoretinal interface. Eye 1992;6:541-552.
15.
Heegaard S, Jensen OA, Prause JU: Structure and composition of the inner limiting membrane of the retina. SEM on frozen resin-cracked and enzyme-digested retinas of Macaca mulatta. Graefes Arch Clin Exp Ophthalmol 1986;224:355-360.
16.
Jerdan J, Kao L-Y, Glaser B: The inner limiting membrane: a modified basement membrane? Invest Ophthalmol Vis Sci 1986;27(suppl):230.
17.
Kohno T, Sorgente N, Goodnight R, Ryan SJ: Alterations in the distribution of fibronectin and laminin in the diabetic human eye. Invest Ophthalmol Vis Sci 1987;28:515-521.
18.
Kohno T, Sorgente N, Ishibashi T, Goodnight R, Ryan SJ: Immunofluorescent studies of fibronectin and laminin in the human eye. Invest Ophthalmol Vis Sci 1987;28:506-514.
19.
Sebag J, Hageman GS: Interfaces. Eur J Ophthalmol 2000;10:1-3.
20.
Li X, Shi X, Fan J: Posterior vitreous detachment with plasmin in the isolated human eye. Graefes Arch Clin Exp Ophthalmol 2002;240:56-62.
21.
Uemura A, Nakamura M, Kachi S, Nishizawa Y, Asami T, Miyake Y, Terasaki H: Effect of plasmin on laminin and fibronectin during plasmin-assisted vitrectomy. Arch Ophthalmol 2005;123:209-213.
22.
Oliveira LB, Tatebayashi M, Mahmoud TH, Blackmon SM, Wong F, McCuen BW II: Dispase facilitates posterior vitreous detachment during vitrectomy in young pigs. Retina 2001;21:342-331.
23.
Gandorfer A, Rohleder M, Sethi C, Eckle D, Welge-Lussen U, Kampik A, Luthert P, Charteris D: Posterior vitreous detachment induced by microplasmin. Invest Ophthalmol Vis Sci 2004;45:641-647.
24.
De Smet MD, Valmaggia C, Zarrantz J, Willekens B: Microplasmin: ex vivo characterization of its activity in porcine vitreous. Invest Ophthalmol Vis Sci 2009;50:814-819.
25.
De Smet MD, Gandorfer A, Stalmans P, Veckeneer M, Feron E, Pakola S, Kampik A: Microplasmin intravitreal administration in patients with vitreomacular traction scheduled for vitrectomy: The MIVI I trial. Ophthalmology 2009;116:1349-1355.
26.
Heegaard S, Jensen OA, Prause JU: Structure of the vitread face of the monkey optic disc (Macaca mulatta). SEM on frozen resin-cracked optin nerveheads supplemented by TEM and immunohistochemistry. Graefes Arch Clin Exp Ophthalmol 1988;226:377-383.
27.
Sebag J: Molecular biology of pharmacologic vitreolysis. Trans Am Ophthalmol Soc 2005;103:473-494.
28.
Matsumoto B, Blanks JC, Ryan SJ: Topographic variations in the rabbit and primate internal limiting membrane. Invest Ophthalmol Vis Sci 1984;25:71-82.
29.
Foos RY: Vitreoretinal juncture; topographical variations. Invest Ophthalmol Vis Sci 1972;11:801-808.
30.
Hogan MJ: The vitreous, its structure, and relation to the ciliary body and retina. Proctor award lecture. Invest Ophthalmol Vis Sci 1963;2:418-445.
31.
Johnson MW: How should we release vitreomacular traction: surgically, pharmacologically, or pneumatically? Am J Ophthalmol 2013;155:203-205.
32.
Johnson MW: Posterior vitreous detachment: evolution and complications of its early stages. Am J Ophthalmol 2010;149:371-382.
33.
Itakura H, Kishi S: Aging changes of vitreomacular interface. Retina 2011;31:1400-1404.
34.
Los LI, van der Worp RJ, van Luyn MJ, Hooymans JM: Age-related liquefaction of the human vitreous body: LM and TEM evaluation of the role of proteoglycans and collagen. Invest Ophthalmol Vis Sci 2003;44:2828-2833.
35.
Foos RY, Wheeler NC: Vitreretinal juncture. Synchysis senilis and posterior vitreous detachment. Ophthalmology 1982;89:1502-1512.
36.
Ueno N, Sebag J, Hirokawa H, Chakrabarti B: Effects of visible light irradiation on vitreous structure in the presence of photosensitizer. Exp Eye Res 1987;44:863-870.
37.
Foos RY: Ultrastructural features of posterior vitreous detachment. Graefes Arch Clin Exp Ophthalmol 1975;196:103-111.
38.
Foos RY: Posterior vitreous detachment. Trans Am Acad Ophthalmol Otol 1972;76:480-497.
39.
Kamei A, Totani A: Isolation and characterization of minor glycosaminoglycans in the rabbit vitreous body. Biochem Biophys Res Commun 1982;109:881-887.
40.
Staubach F, Nober V, Janknecht P: Enzyme-assisted vitrectomy in enucleated pig eyes: a comparison of hyaluronidase, chondroitinase, and plasmin. Curr Eye Res 2004;29:261-268.
41.
Gad Elkareem AM, de Smet M: Effect of microplasmin on the clearance of vitreous hemorrhage from an experimental model in rabbits. Acta Ophthalmol 2012, DOI: 10.1111/j.1755-3768.2012.02568.x.
42.
Sebag J: Vitreoschisis. Graefes Arch Clin Exp Ophthalmol 2008;246:329-332.
43.
Chu TG, Lopez PF, Cano MR, Freeman WR, Lean JS, Liggett PE, Thomas EL, Green RL: Posterior vitreoschisis. an echographic finding in proliferative diabetic retinopathy. Ophthalmology 1996;103:315-322.
44.
Sebag J, Buckingham B, Charles MA, Reiser K: Biochemical abnormalities in vitreous of humans with proliferative diabetic retinopathy. Arch Ophthalmol 1992;110:1472-1476.
45.
Kishi S, Demaria C, Shimizu K: Vitreous cortex remnants at the fovea after spontaneous vitreous detachment. Int Ophthalmol 1986;9:253-260.
46.
Wang MY, Nguyen D, Hindoyan N, Sadun AA, Sebag J: Vitreo-papillary adhesion in macular hole and macular pucker. Retina 2009;29:644-650.
47.
Sebag J, Wang MY, Nguyen D, Sadun AA: Vitreopapillary adhesion in macular diseases. Trans Am Ophthalmol Soc 2009;107:35-46.
48.
Bottos JM, Elizalde J, Rodrigues EB, Maia M: Current concepts in vitreomacular traction syndrome. Curr Opin Ophthalmol 2012;23:195-201.
49.
Klöti R: Experimental occlusion of retinal and ciliary vessels in owl monkeys. I. Technique and clinical observations of selective embolism of the central retinal artery system. Exp Eye Res 1967;6:393-399.
50.
Linder B: Acute posterior vitreous detachment and its retinal complications. Acta Ophthalmol Suppl 1966;87:5-107.
51.
Sebag J: Aging of the vitreous. Eye 1987;1:254-262.
52.
Foos RY, Kreiger AE, Forsythe AB, Zakka KA: Posterior vitreous detachment in diabetic subjects. Ophthalmology 1980;87:122-128.
53.
Larsson L, Österlin S: Posterior vitreous detachment. A combined clinical and physicochemical study. Graefes Arch Clin Exp Ophthalmol 1985;223:92-95.
54.
Jaffe NS: Complications of acute posterior vitreous detachment. Arch Ophthalmol 1968;79:568-571.
55.
Murakami T, Takagi H, Ohashi H, Kita M, Nishiwaki H, Miyamoto K, Watanabe D, Sakamoto A, Yamaike N, Yoshimura N: Role of posterior vitreous detachment induced by intravitreal tissue plasminogen activator in macular edema with central retinal vein occlusion. Retina 2007;27:1031-1037.
56.
Williamson TH, Watt L, Mokete B: Black or negative flashes in posterior vitreous detachment: a transient symptom before lightning flashes commence. Eye 2009;23:1477.
57.
Hikichi T, Trempe CL: Relationship between floaters, light flashes, or both, and complications of posterior vitreous detachment. Am J Ophthalmol 1994;117:593-598.
58.
Van Overdam K, Wefers Bettink-Remeijer M, Klaver CC, Mulder PG, Moll AC, van Meurs JC: Symptoms and findings predictive for the development of new retinal breaks. Arch Ophthalmol 2005;123:479-484.
59.
Van Overdam KA, Bettink-Remeijer MW, Mulder PG, van Meurs JC: Symptoms predictive for the later development of retinal breaks. Arch Ophthalmol 2001;119:1483-1486.
60.
Moore RF: Subjective ‘lightning streaks'. Br J Ophthalmol 1947;31:46-50.
61.
Goodfellow JF, Mokete B, Williamson TH: Discriminate characteristics of photopsia in posterior vitreous detachment, retinal tears and retinal detachment. Ophthalmic Physiol Optics 2010;30:20-23.
62.
Uchino E, Uenura A, Ohba N: Initial stages of posterior vitreous detachment in healthy eyes of older persons evaluated by optical coherence tomography. Arch Ophthalmol 2001;119:1475-1479.
63.
Gaucher D, Tadayoni R, Erginay A, Haouchine B, Gaudric A, Massin P: Optical coherence tomography assessment of the vitreoretinal relationship in diabetic macular edema. Am J Ophthalmol 2005;139:807-813.
64.
Johnson MW: Perifoveal vitreous detachment and its macular complications. Trans Am Ophthalmol Soc 2005;103:537-567.
65.
Ito Y, Terasaki H, Suzuki T, Kojima T, Mori M, Ishikawa K, Miyake Y: Mapping posterior vitreous detachment by optical coherence tomography in eyes with idiopathic macular hole. Am J Ophthalmol 2003;135:351-355.
66.
Tan HS, Mura M, de Smet MD: Iatrogenic retinal breaks in 25-gauge macular surgery. Am J Ophthalmol 2009;148:427-430.
67.
Kakehashi A, Kado M, Akiba J, Hirokawa H: Variations of posterior vitreous detachment. Br J Ophthalmol 1997;81:527-532.
68.
Mojana F, Kozak I, Oster SF, Cheng L, Bartsch DU, Brar M, Yuson RM, Freeman WR: Observations by spectral-domain optical coherence tomography combined with simultaneous scanning laser ophthalmoscopy: imaging of the vitreous. Am J Ophthalmol 2010;149:641-650.
69.
Tammewar AM, Bartsch DU, Kozak I, Rosen R, Falkenstein IA, Garcia P, Freeman WR: Imaging vitreomacular interface abnormalities in the coronal plane by simultaneous combined scanning laser and optical coherence tomography. Br J Ophthalmol 2009;93:366-372.
70.
De Croos FC, Toth CA, Folgar FA, Pakola S, Stinnett SS, Heydary CS, Burns R, Jaffe GJ: Characterization of vitreoretinal interface disorders using OCT in the interventional phase 3 trials of ocriplasmin. Invest Ophthalmol Vis Sci 2012;53:6504-6511.
71.
Sebag J, Balazs EA: Pathogenesis of cystoid macular edema: an anatomic consideration of vitreoretinal adhesions. Surv Ophthalmol 1984;28(suppl):493-498.
72.
Mirza RG, Johnson MW, Jampol LM: Optical coherence tomography use in evaluation of the vitreoretinal interface: a review. Surv Ophthalmol 2007;52:397-421.
73.
Pischel DK: Detachment of the vitreous as seen with slit-lamp examination. Trans Am Ophthalmol Soc 1952;50:329-346.
74.
Johnson MW: Posterior vitreous detachment. Evolution and role in macular disease. Retina 2012;32:S174-S178.
75.
Akiba J: Prevalence of posterior vitreous detachment in high myopia. Ophthalmology 1993;100:1384-1388.
76.
Wu PC, Chen YJ, Chen YH, Chen CH, Shin SJ, Tsai CL, Kuo HK: Factors associated with foveoschisis and foveal detachment without macular hole in high myopia. Eye 2009;23:356-361.
77.
Yonemoto J, Ideta H, Sasaki K, Tanaka S, Hirose A, Oka C: The age of onset of posterior vitreous detachment. Graefes Arch Clin Exp Ophthalmol 1994;232:67-70.
78.
Novak MA, Welch RB: Complications of acute symptomatic posterior vitreous detachment. Am J Ophthalmol 1984;97:308-314.
79.
Sirek OV, Sirek A, Fikar K: The effect of sex hormones on glycosaminoglycan content of canine aorta and coronary arteries. Atherosclerosis 1977;27:227-233.
80.
Hayreh SS, Joans JB: Posterior vitreous detachment: clinical correlations. Ophthalmologica 2004;218:333-343.
81.
McDonnell PH, Patel A, Green WR: Comparison of intracapsular and extracapsular cataract surgery - histopathologic study of eyes obtained postmortem. Ophthalmology 1985;92:1208-1225.
82.
Hyams SW, Neumann E, Friedman Z: Myopia-aphakia. II. Vitreous and peripheral retina. Br J Ophthalmol 1975;59:483-485.
83.
Schubert HD, Morris WJ, Trokel SL, Balazs EA: The role of vitreous in the intraocular pressure rise after Nd:YAG laser capsulotomy. Arch Ophthalmol 1985;103:1538-1542.
84.
Österlin S: On the molecular biology of the vitreous in the aphakic eye. Acta Ophthalmol 1977;55:353-361.
85.
Sebag J: Anomalous posterior vitreous detachment: a unifying concept in vitreo-retinal disease. Graefes Arch Clin Exp Ophthalmol 2004;242:690-698.
86.
Simpson AR, Petrarca R, Jackson TL: Vitreomacular adhesion and neovascular age-related macular degeneration. Surv Ophthalmol 2012;57:498-509.
87.
Michalewska Z, Michalewski J, Sikorski BL, Kaluzny JJ, Wojtkowski M, Adelman RA, Nawrocki J: A study of macular hole formation by serial spectral optical coherence tomography. Clin Experiment Ophthalmol 2009;37:373-383.
88.
Kakehashi A, Schepens CL, de Sousa-Neto A, Jalkh AE, Trempe CL: Biomicroscopic findings of posterior vitreoschisis. Ophthalmol Surg 1993;24:846-850.
89.
Stickler GB, Belau PG, Farrell FJ, Jones JD, Pugh DG, Steinberg AG, Ward LE: Hereditary progressive arthro-ophthalmopathy. Mayo Clin Proc 1965;40:443-455.
90.
Edwards AO: Clinical features of the congenital vitreoretinopathies. Eye 2008;22:1233-1242.
91.
Hirokawa H, Takahashi M, Trempe CL: Vitreous changes in peripheral uveitis. Arch Ophthalmol 1985;103:1704-1707.
92.
Hikichi T, Trempe CL: Role of vitreous in the prognosis of peripheral uveitis. Am J Ophthalmol 1993;116:401-405.
93.
Sebag J: Abnormalities of human vitreous structure in diabetes. Graefes Arch Clin Exp Ophthalmol 1993;231:257-260.
94.
Mitry D, Singh J, Yorston D, Siddiqui MA, Wright A, Fleck BW, Campbell H, Charteris DG: The predisposing pathology and clinical characteristics in the Scottish Retinal Detachment Study. Ophthalmology 2011;118:1429-1434.
95.
Gallemore RP, Jumper JM, McCuen BW, Jaffe GJ, Postel EA, Toth CA: Diagnosis of vitreoretinal adhesions in macular disease with optical coherence tomography. Retina 2000;20:115-120.
96.
Folgar FA, Toth CA, De Croos FC, Girach A, Pakola S, Jaffe GJ: Assessment of retinal morphology with spectral and time domain OCT in the phase III trials of enzymatic vitreolysis. Invest Ophthalmol Vis Sci 2012;53:7395-7401.
97.
Barak Y, Ihnen MA, Schaal S: Spectral domain optical coherence tomography in the diagnosis and management of vitreoretinal interface pathologies. J Ophthalmol 2012;2012:876472.
98.
Hillenkamp J, Kraus J, Framme C, Jackson TL, Roider J, Gabel V-P, Sachs HG: Retreatment of full-thickness macular hole: predictive value of optical coherence tomography. Br J Ophthalmol 2007;91:1445-1449.
99.
Takezawa M, Toyoda F, Kambara C, Yamagami H, Kakehashi A: Clarifying the mechanism of idiopathic macular hole development in fellow eyes using spectral-domain optical coherence tomography. Clin Ophthalmol 2011;5:101-108.
100.
Chauhan DS, Antcliff RJ, Rai PA, Williamson TH, Marshall J: Papillofoveal traction in macular hole formation: the role of optical coherence tomography. Arch Ophthalmol 2000;118:32-38.
101.
Massin P, Duguid G, Erginay A, Haouchine B, Gaudric A: Optical coherence tomography for evaluating diabetic macular edema before and after vitrectomy. Am J Ophthalmol 2003;135:169-177.
102.
Gupta P, Sadun AA, Sebag J: Multifocal retinal contraction in macular pucker analyzed with combined optical coherence tomography/scanning laser ophthalmoscopy. Retina 2008;28:447-452.
103.
Koizumi H, Spaide RF, Fisher YL, Freund KB, Klancnik JM Jr, Yannuzzi LA: Three-dimensional evaluation of vitreomacular traction and epiretinal membrane using spectral-domain optical coherence tomography. Am J Ophthalmol 2008;145:509-517.
104.
Rosen R, van Velthoven M, Garcia P, Cucu RG, de Smet MD, Muldoon TO, Podoleanu AG: Ultrahigh-resolution combined coronal optical coherence tomography confocal scanning ophthalmoscope (OCT/SLO): a pilot study. Spektrum Augenheilkd 2007;21:36-47.
105.
Van Velthoven MEJ, Faber DJ, Verbraak FD, van Leeuwen TG, de Smet MD: Recent developments in optical coherence tomography for imaging the retina. Prog Ret Eye Res 2007;26:57-77.
106.
Van Velthoven MEJ, Verbraak FD, Yannuzzi LA, Rosen RB, Podoleanu AG, de Smet MD: Imaging the retina by en face optical coherence tomography. Retina 2006;26:129-136.
107.
Van Velthoven MEJ, Verbraak FD, Garcia PM, Schlingemann RO, Rosen RB, de Smet M: Evaluation of central serous retinopathy with en face optical coherence tomography. Br J Ophthalmol 2005;89:1483-1488.
108.
Legarreta JE, Gregorio G, Knighton RW, Punjabi OS, Lalwani GA, Puliafito CA: Three-dimensional spectral-domain optical coherence tomography images of the retina in the presence of epiretinal membrane. Am J Ophthalmol 2008;145:102-103.
109.
Sebag J: Imaging vitreous. Eye 2002;16:429-439.
110.
Kicova N, Bertelmann T, Irle S, Sekundo W, Mennel S: Evaluation of a posterior vitreous detachment: a comparison of biomicroscopy, B-scan ultrasonography and optical coherence tomography to surgical findings with chromodissection. Acta Ophthalmol 2012;90:e264-e268.
111.
Arzabe CW, Akiba J, Jalkh AE, Quiroz MA, Trempe CL, McMeel JW, Celorio JM: Comparative study of vitreoretinal relationships using biomicroscopy and ultrasound. Graefes Arch Clin Exp Ophthalmol 1991;229:66-68.
112.
Hosseini H, Anvari-Ardakani H, Karanjam M, Farvardin M, Nowroozizadeh S: Ultrasonographic pictures of intravitreal triamcinolone acetonide. Eur J Ophthalmol 2009;19:263-267.
113.
Van Newkirk MR, Johnson MW, Hughes JR, Meyer KA, Byrne SF: B-scan ultrasonographic findings in the stages of idiopathic macular hole. Trans Am Ophthalmol Soc 2000;98:163-169.
114.
Falkner-Radler CI, Glittenberg C, Hagen S, Benesch T, Binder S: Spectral-domain optical coherence tomography for monitoring epiretinal membrane surgery. Ophthalmology 2010;117:798-805.
115.
Krebs I, Glittenberg C, Zeiler F, Binder S: Spectral domain optical coherence tomography for higher precision in the evaluation of vitreoretinal adhesions in exudative age-related macular degeneration. Br J Ophthalmol 2011;95:1415-1418.
116.
Takahashi M, Trempe CL, Maguire K, McMeel W: Vitreoretinal relationship in diabetic retinopathy: a biomicroscopic evaluation. Arch Ophthalmol 1981;99:241-245.
117.
Tagawa H, McMeel JW, Furukawa H, Quiroz H, Murakami K, Takahashi M, Trempe CL: Role of the vitreous in diabetic retinopathy. 1. Vitreous changes in diabetic retinopathy and in physiologic aging. Ophthalmology 1986;93:596-601.
118.
Akiba J, Arzabe CW, Trempe CL: Posterior vitreous detachment and neovascularization in diabetic retinopathy. Ophthalmology 1990;97:889-891.
119.
Ono R, Kakehashi A, Yamagami H, Sugi N, Kinoshita N, Saito T, Tamemoto H, Kuroki M, Ishikawa S, Kawakami M: Prospective assessment of proliferative diabetic retinopathy with observations of posterior vitreous detachment. Int Ophthalmol 2005;26:15-19.
120.
Jalkh A, Takahashi M, Topilow HW, Trempe CL, McMeel JW: Prognostic value of vitreous findings in diabetic retinopathy. Arch Ophthalmol 1982;100:432-434.
121.
Trempe CL, Takahashi M, Topilow HW: Vitreous changes in retinal branch vein occlusion. Ophthalmology 1981;88:681-687.
122.
Akiba J, Kado M, Kakehashi A, Trempe CL: Role of the vitreous in posterior segment neovascularizatioin in central retinal vein occlusion. Ophthalmol Surg 1991;22:498-502.
123.
Hikichi T, Konno S, Trempe CL: Role of the vitreous in central retinal vein occlusion. Retina 1995;15:29-33.
124.
Kado M, Trempe CL: Role of the vitreous in branch retinal vein occlusion. Am J Ophthalmol 1988;105:20-24.
125.
Avunduk AM, Cetinkaya K, Kapicioğlu Z, Kaya C: The effect of posterior vitreous detachment on the prognosis of branch retinal vein occlusion. Acta Ophthalmol Scand 1997;75:441-442.
126.
Kado M, Jalkh AE, Yoshida A, Takahashi M, Wazen N, Trempe CL, Schepens CL: Vitreous changes and macular edema in central retinal vein occlusion. Ophthalmic Surg 1990;21:544-549.
127.
Bertelmann T, Kicova N, Messerschmidt-Roth A, Irle S, Sekundo W, Mennel S: The vitreomacular interface in retinal vein occlusion. Acta Ophthalmol 2011;89:e327-e331.
128.
Martinez MR, Ophir A: Extrafoveal traction in retinal vein occlusion using spectral domain optical coherence tomography. Graefes Arch Clin Exp Ophthalmol 2011;249:811-820.
129.
Jaffe NS: Vitreous traction at the posterior pole of the fundus due to alterations in the vitreous posterior. Trans Am Acad Ophthalmol Otolaryngol 1967;71:642-652.
130.
Levy J, Klemperer I, Belfair N, Rogozin A, Lifshitz T: Rapid spontaneous resolution of vitreomacular traction syndrome documented by optical coherence tomography. Int Ophthalmol 2004;25:247-251.
131.
Yamashita T, Uemara A, Uchino E, Doi N, Ohba N: Spontaneous closure of traumatic macular hole. Am J Ophthalmol 2002;133:230-235.
132.
Lai MM, Bressler SB, Haller JA: Spontaneous resolution of macular microhole. Am J Ophthalmol 2006;141:210-212.
133.
Cheng CL, Hoh ST, Chuan JCY, Wong EYM, Koh AHC: Acute vitreomacular traction with early spontaneous resolution. Clin Exp Ophthalmol 2003;31:161-163.
134.
Ebato K, Kishi S: Spontaneous closure of macular hole after posterior vitreous detachment. Ophthmic Surg Lasers 2000;31:245-247.
135.
Nasrallah FP, Jalkh AE, Van Coppenolle F, Kado M, Trempe CL, McMeel JW, Schepens CL: The role of the vitreous in diabetic macular edema. Ophthalmology 1988;95:1335-1339.
136.
Nasrallah FP, van de Velde F, Jalkh AE, Trempe CL, McMeel JW, Schepens CL: Importance of the vitreous in young diabetics with macular edema. Ophthalmology 1989;96:1511-1516.
137.
Roldan M, Serrano JM: Macular edema and vitreous detachment. Ann Ophthalmol 1989;21:141-148.
138.
Ikeda T, Fujikado T, Tano Y, Tsujikawa K, Koizumi K, Sawa H, Yasuhara T, Maeda K, Kinoshita S: Vitrectomy for rhegmatogenous or tractional retinal detachment with familial exudative vitreoretinopathy. Ophthalmology 1999;106:1081-1085.
139.
Takahashi MK, Hikichi T, Akiba J, Yoshida A, Trempe CL: Role of the vitreous and macular edema in branch retinal vein occlusion. Ophthalmic Surg Lasers 1997;28:294-299.
140.
Hikichi T, Akiba J, Trempe CL: Effect of the vitreous on the prognosis of full-thickness idiopathic macular hole. Arch Ophthalmol 1993;116:273-278.
141.
Hikichi T, Yoshida A, Trempe CL: Course of vitreomacular traction syndrome. Am J Ophthalmol 1995;119:55-61.
142.
Hikichi T, Fujio N, Akiba J, Azuma Y, Takahashi M, Yoshida A: Association between the short-term natural history of diabetic macular edema and the vitreomacular relationship in type II diabetes mellitus. Ophthalmology 1997;104:473-478.
143.
Yamaguchi Y, Otani T, Kishi S: Resolution of diabetic cystoid macular edema associated with spontaneous vitreofoveal separation. Am J Ophthalmol 2003;135:116-118.
144.
Carpineto P, Ciancaglini M, Aharrh-Gnama A, Agnifili L, Mastropasqua L: Optical coherence tomography and retinal thickness analyzer features of spontaneous resolution of vitreomacular traction syndrome: a case report. Eur J Ophthalmol 2004;14:67-70.
145.
Takahashi A, Yoshida A, Nagaoka T, Takamiya A, Sato E, Kagokawa H, Kameyama D, Sogawa K, Ishiko S, Hirokawa H: Idiopathic full-thickness macular holes and the vitreomacular interface: a high-resolution spectral-domain optical coherence tomography study. Am J Ophthalmol 2012;154:881-892.
146.
Trempe CL, Weiter JJ, Furukawa H: Fellow eyes in cases of macular hole. Biomicroscopic study of the vitreous. Arch Ophthalmol 1986;104:93-95.
147.
Kakehashi A, Schepens CL, Trempe CL: Vitreomacular observations. II. Data on the pathogenesis of idiopathic macular breaks. Graefes Arch Clin Exp Ophthalmol 1996;234:425-433.
148.
Johnson RN, Gass JD: Idiopathic macular holes. Observations, stages of formation, and implications for surgical intervention. Ophthalmology 1988;95:917-924.
149.
Akiba J, Quiroz MA, Trempe CL: Role of posterior vitreous detachment in idiopathic macular holes. Ophthalmology 1990;97:1610-1613.
150.
Gass JDM: Idiopathic senile macular hole. Its early stages and pathogenesis. Arch Ophthalmol 1988;106:629-639.
151.
Akiba J, Yoshida A, Trempe CL: Risk of developing a macular hole. Arch Ophthalmol 1990;108:1088-1090.
152.
Haouchine B, Massin P, Gaudric A: Foveal pseudocyst as the first step in macular hole formation: a prospective study by optical coherence tomography. Ophthalmology 2001;108:15-22.
153.
Kraus CL, Rao PK, Apte RS: Effect of preoperative vitreous status on visual outcomes following vitrectomy for epiretinal membrane repair. Can J Ophthalmol 2011;46:186-190.
154.
Weber-Krause B, Eckardt U: Incidence of posterior vitreous detachment in eyes with and without age-related macular degeneration: an ultrasound study. Ophthalmologe 1996;93:660-665.
155.
Quaranta-El Maftouhi M, Mauget-Fayesse M: Anomalous vitreoretinal adhesions in patients with exudative age-related macular degeration: an OCT study. Eur J Ophthalmol 2006;16:134-137.
156.
Öndes F, Yilmaz G, Acar MA, Ünlü N, Kocaoḡlan H, Arsan AK: Role of the vitreous in age-related macular degeneration. Jpn J Ophthalmol 2000;44:91-93.
157.
Krebs I, Brannath W, Glittenberg C, Zeiler F, Sebag J, Binder S: Posterior vitreomacular adhesion: a potential risk factor for exudative age-related macular degeneration? Am J Ophthalmol 2007;144:741-746.
158.
Robison CD, Krebs I, Binder S, Barbazetto IA, Kotsolis AI, Yannuzzi LA, Sadun AA, Sebag J: Vitreomacular adhesion in active and end-stage age-related macular degeneration. Am J Ophthalmol 2009;148:79-82.
159.
Nomura Y, Ueta T, Iriyama A, Inoue Y, Obata R, Tamaki Y, Yamaguchi T, Yanagi Y: Vitreomacular interface in typical exudative age-related macular degeneration and polypoidal choroidal vasculopathy. Ophthalmology 2011;118:853-859.
160.
Serpetopoulos C: Optical explanation of the gradual disappearance of flying dots in posterior vitreous detachment. Surv Ophthalmol 1997;42:92-94.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.